The selectivity of [Pt(O,O’-acac)(γ-acac)(DMS)] stimulates a more detailed study aimed at pre-clinical investigation of its therapeutic potential in vivo. In this context, we employed a preclinical model based on the subcutaneous injection of MCF-7 breast cancer and ZL55 malignant pleural mesotelioma cell lines in SCID mice. Remarkably, [Pt(O,O’-acac)(γ- acac)(DMS)] stands out for higher anticancer activity than cisplatin toward both the murine tumor models examined, inducing up to 50% inhibition of tumor growth. We also demonstrated enhanced in vivo pharmacokinetics (PK), biodistribution and tolerability of [Pt(O,O’-acac)(γ-acac)(DMS)] when compared to cisplatin administered in Wistar rats. Altogether, these findings suggest that [Pt(O,O’-acac)(γ-acac)(DMS)] is a promising therapeutic agent for preventing growth of cancer, thus providing a solid starting point for its validation as a suitable candidate for further pharmacological testing.

[Pt(O,O’-acac)(γ-acac)(DMS)]: in vivo Studies of a Promising Anticancer Drug in Cancer Therapy

VETRUGNO, CARLA;MIGONI, DANILO;FANIZZI, Francesco Paolo;DE PASCALI, SANDRA ANGELICA;MARSIGLIANTE, Santo;MUSCELLA, Antonella
2014

Abstract

The selectivity of [Pt(O,O’-acac)(γ-acac)(DMS)] stimulates a more detailed study aimed at pre-clinical investigation of its therapeutic potential in vivo. In this context, we employed a preclinical model based on the subcutaneous injection of MCF-7 breast cancer and ZL55 malignant pleural mesotelioma cell lines in SCID mice. Remarkably, [Pt(O,O’-acac)(γ- acac)(DMS)] stands out for higher anticancer activity than cisplatin toward both the murine tumor models examined, inducing up to 50% inhibition of tumor growth. We also demonstrated enhanced in vivo pharmacokinetics (PK), biodistribution and tolerability of [Pt(O,O’-acac)(γ-acac)(DMS)] when compared to cisplatin administered in Wistar rats. Altogether, these findings suggest that [Pt(O,O’-acac)(γ-acac)(DMS)] is a promising therapeutic agent for preventing growth of cancer, thus providing a solid starting point for its validation as a suitable candidate for further pharmacological testing.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11587/410223
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact